Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells: Mechanism for TPMT protein deficiency inherited by TPMT*2, TPMT*3A, TPMT*3B or TPMT*3C

Pharmacogenetics

Volumn 9, Issue 5, 1999, Pages 641-650

  Tai, Hung Liang ^a,b   Fessing, Michael Y ^a,b   Bonten, Eric J ^a   Yanishevsky, Yuri ^a   D'Azzo, Alessandra ^a   Krynetski, Eugene Y ^a,b   Evans, William E ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Proteasome; Proteolysis; Thiopurine S methyltransferase

Indexed keywords

ADENOSINE TRIPHOSPHATE; CALPASTATIN; CELL PROTEIN; COMPLEMENTARY DNA; LACTACYSTIN; MUTANT PROTEIN; PROTEASOME; PROTEASOME INHIBITOR; RECOMBINANT PROTEIN; THIOPURINE METHYLTRANSFERASE;

ANIMAL CELL; ARTICLE; CELL STRAIN COS1; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME DEGRADATION; INHERITANCE; MAMMAL CELL; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RETICULOCYTE LYSATE; WESTERN BLOTTING;

ADENOSINE TRIPHOSPHATE; ALLELES; ANIMALS; COS CELLS; CYSTEINE ENDOPEPTIDASES; DNA, COMPLEMENTARY; HUMANS; KINETICS; METHYLTRANSFERASES; MULTIENZYME COMPLEXES; MUTATION; PROTEASOME ENDOPEPTIDASE COMPLEX; RABBITS; RECOMBINANT PROTEINS; RETICULOCYTES; S-ADENOSYLMETHIONINE; TRANSFECTION;

ANIMALIA; MAMMALIA; ORYCTOLAGUS CUNICULUS; STAPHYLOCOCCUS PHAGE 3A;

EID: 0032693405     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Ameyaw MM, Collie-Duguld ESR, Oforl-Adgel D, McLeod HL. Thiopurne methyltransferase alleles in British and Ghanaian populations. Hum Mol Genet 1999; 8:367-370.
2. Bonten E, van der Spoel A, Fornerod M, Grosveld G, d'Azzo A. Characterization of human lysosomal neuraminidase defines the molecular basis of the metabolic storage disorder sialidosis. Genes Dev 1996; 10:3156-3169.
3. Chamberlain JP. Fluorographic detection of radioactivity in polyacrylamide gels with water-soluble fluor, sodium salicylate. Analytical Biochem 1979; 98:132-135.
4. Collie-Duguid ESR, Pritchard SC, Powrie RH, Sludden J, Collier D, Li T, McLeod HL. The frequency and distribution of thiopurine methyltransferase (TPMT) alleles in Caucasians and Asian populations. Pharmacogenetics 1999; 9:37-42.
5. de la Moureyre CSV, Debuysere H, Sabbagh N, Marez D, Vinner E, Chevalier ED, et al. Detection of known and new mutations in the thiopurine S-methyltransferase gene by single-strand conformation polymorphism analysis. Hum Mutat 1998; 12:177-185.
6. Dice JF. Peptide sequences that target cytosolic proteins for lysosomal proteolysis. Trends Biochem Sci 1990; 15:305-309.
7. Fenteany G, Schreiber SL. Lactacystin, proteasome function, and cell fate. J Biol Chem 1998; 273:8545-8548.
8. Gluzman Y. SV40-transformed simian cells support the replication of early SV40 mutants. Cell 1981; 23:175-182.
9. Hegde AN, Goldberg AL, Schwartz JH. Regulatory subunits of cAMP-dependent protein kinases are degraded after conjugation to ubiquitin: a molecular mechanism underlying long-term synaptic plasticity. Proc Natl Acad Sci USA 1993; 90:7436-7440.
10. Hershko A, Ciechanover A. The ubiquitin system for protein degradation. Annu Rev Biochem 1992; 61:761-807.
11. Hochstrasser M, Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. Curr Opin Cell Biol 1995; 7:215-223.
12. Hon YY, Fessing MY, Pui CH, Relling MV, Krynetski EY, Evans WE. Polymorphism of the thiopurine S-methyltransferase (TPMT) gene in African Americans. Hum Mol Genet 1999; 8:371-376.
13. Krynetski EY, Evans WE. Pharmacogenetics of cancer therapy: getting personal. Am J Hum Genet 1998; 63:11-16.
14. Krynetski EY, Schuetz JD, Galpin AJ, Pui CH, Relling MV, Evans WE. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci USA 1995; 92:949-953.
15. Krynetski EY, Tai HL, Yates CR, Fessing MY, Loennechen T, Schuetz JD, et al. Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics 1996; 6:279-290.
16. Lee DH, Goldberg AL. Selective inhibitors of the proteasome-dependent and vacuolar pathways of protein degradation in Saccharomyces cerevisiae. J Biol Chem 1996; 271:27280-27284.
17. Loennechen T, Yates CR, Fessing MY, Relling MV, Krynetski EY, Evans WE. Isolation of a human thiopurine S-methyltransferase (TPMT) complementary DNA with a single nucleotide transition A719G (TPMT*3C) and its association with loss of TPMT protein and catalytic activity in humans. Clin Pharmacol Ther 1998; 64:46-51.
18. Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melen K, Julkunen I, Taskinen J. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 1995; 34:4202-4210.
19. Mayer A, Siegel NR, Schwartz AL, Ciechanover A. Degradation of proteins with acetylated amino termini by the ubiquitin system. Science 1989; 244:1480-1483.
20. McLeod HL, Lin JS, Scott EP, Pui CH, Evans WE. Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther 1994; 55:15-20.
21. Murakami Y, Matsufuji S, Kameji T, Hayashi S, Igarashi K, Tamura T, et al. Ornithine decarboxylase is degraded by the 26S proteasome without ubiquitination. Nature 1992; 360:597-599.
22. Otterness D, Szumlanski C, Lennard L, Klemetsdal B, Aarbakke J. Park-Hah JO, et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther 1997; 62:60-73.
23. Otterness DM, Szumlanski CL, Wood TC, Weinshilboum RM. Human thiopurine methyltransferase pharmacogenetics. Kindred with a terminal exon splice junction mutation that results in loss of activity. J Clin Invest 1998; 101:1036-1044.
24. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994; 78:761-771.
25. Szumlanski C, Otterness D, Her C, Lee D, Brandriff B, Kelsell D, et al. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol 1996; 15:17-30.
26. Tai HL, Krynetski EY, Yates CR, Loennechen T, Fessing MY, Krynetskaia NF, Evans WE. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet 1996; 58:694-702.
27. Tai HL, Krynetski EY, Schuetz EG, Yanishevski Y, Evans WE. Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. Proc Natl Acad Sci USA 1997; 94:6444-6449.
28. van Dongen JM, Willemsen R, Ginns EI, Sips HJ, Tager JM, Barranger JA, Reuser AJ. The subcellular localization of soluble and membrane- bound lysosomal enzymes in 1-cell fibroblasts: a comparative immunocytochemical study. Eur J Cell Biol 1985; 39:179-189.
29. Varshavsky A. The N-end rule. Cell 1992; 69:725-735.
30. Varshavsky A. The ubiquitin system. Trends Biochem Sci 1997; 22:383-387.
31. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32:651-662.
32. Wilkinson KD. Detection and inhibition of ubiquitin-dependent proteolysis. Methods Enzymol 1990; 185:387-397.
33. Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, Pui CH, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997; 126:608-614.